WashU Expert: Kinch offers advice to FDA, NIH on drug industry

Pharmaceutical industry has run off the rails, an expert warns. Cost is just a symptom

Michael S. Kinch, associate vice chancellor and professor of biochemistry and molecular biophysics in the School of Medicine at Washington University in St. Louis, is director of the Centers for Research Innovation in Biotechnology & Drug Discovery at the university. He is also author of the newly published “Prescription for Change,” an analysis of the looming crisis in the pharmaceutical industry:


“Healthcare coverage and costs are just the start of it. The new administration  faces a looming crisis in our fundamental ability to continue introducing new medicines. The old system is faltering and nearing failure, creating both a potential crisis and fantastic opportunity. Strong leadership skills will be needed to ensure that we can continue delivering much-needed improvements to health. While we still await the selection of leadership for the Food & Drug Administration, National Institutes of Health and other key organizations, the rumored candidates for these positions raise serious concerns whether the new president fully realizes the implications of these decisions.”

To read more about “Prescription for Change,” visit the Washington University Newsroom.

Read more “First 100 Days” messages at Election2016.wustl.edu.

Leave a Comment

Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.